Chandra Bhagat Pharma
Mumbai, India· Est.
Indian pharma exporter with 80‑year legacy, offering GMP‑grade medicines across oncology, cardiovascular and anti‑infective markets.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Indian pharma exporter with 80‑year legacy, offering GMP‑grade medicines across oncology, cardiovascular and anti‑infective markets.
OncologyCardiovascularInfectious DiseasesHormone Therapy
Technology Platform
Conventional GMP‑compliant formulation and manufacturing of generic medicines, supported by a cold‑chain logistics network and robust regulatory affairs capabilities.
Opportunities
Expansion of cold‑chain logistics and entry into high‑margin injectable and biosimilar markets offer significant export growth potential.
Risk Factors
Regulatory compliance across diverse markets, intense price competition from larger Indian generics firms, and reliance on third‑party API suppliers pose key risks.
Competitive Landscape
CBC competes with Indian generic exporters such as Sun Pharma, Cipla, and Lupin; its differentiation lies in specialized cold‑chain capabilities and a broad portfolio of dosage forms.